Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan Pinning 2005 Profitability Hopes On Antegren, Prialt Launches

Executive Summary

Elan expects to return to profitability in 2005 with the potential launches of Antegren for multiple sclerosis and Crohn's disease and Prialt for chronic pain

You may also be interested in...



Elan Prialt Clears FDA; Half Of Projected Market Does Not Have Delivery Pump

Elan estimates that more than half of the 120,000 potential users of its non-opioid analgesic Prialt do not already possess an internal drug delivery pump expected to be used in ziconotide administrations

Elan Prialt Clears FDA; Half Of Projected Market Does Not Have Delivery Pump

Elan estimates that more than half of the 120,000 potential users of its non-opioid analgesic Prialt do not already possess an internal drug delivery pump expected to be used in ziconotide administrations

Eisai acquires Elan’s Zonegran

Eisai acquires Elan anti-epilepsy agent Zonegran (zonisamide) for $130 mil., plus up to $110 mil. in milestone payments. Eisai also will hire 100 of Elan's sales reps to market the product. Acquisition is part of Eisai's strategy to grow its neurological franchise and its presence in the U.S. Elan's divestiture is one of several used to raise cash ahead of key launches, including Antegren for multiple sclerosis and Crohn's disease in 2005 (1"The Pink Sheet" Feb. 23, 2004, p. 25)...

Related Content

UsernamePublicRestriction

Register

PS043378

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel